DSV Panalpina A/S
15.2.2021 14:32:51 CET | Globenewswire | Press release
Company Announcement No. 865
On 15 February 2021, S&P Global Ratings upgraded DSV Panalpina to "A-" (A minus) with a stable outlook.
S&P Global Ratings states that the "Danish freight forwarder and logistics provider DSV Panalpina A/S has demonstrated resilient operating performance throughout the COVID-19 pandemic and improved EBIT margins earlier than we expected, thanks to the successful integration of the Panalpina acquisition and cost-reduction initiatives.".
"The upgrade to A minus from S&P is a quality stamp for DSV Panalpina. It acknowledges the resiliency of our business model, our ability to integrate Panalpina successfully and our continuous focus on improving our operating performance," says Group CFO Jens Lund.
DSV Panalpina A/S now has the following credit ratings:
S&P Global Ratings A- with a stable outlook
Moody’s A3 with a stable outlook
Any questions may be addressed to Executive Vice President, Investor Relations, Flemming Ole Nielsen, tel. +45 43 20 33 92.
Yours sincerely,
DSV Panalpina A/S
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Rocket Lab Corporation28.3.2026 11:39:53 CET | Press release
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
Vivoryon Therapeutics N.V.28.3.2026 07:00:00 CET | Press release
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
